WithdrawnPhase 1

CLBS119 for Repair of COVID-19 Induced Pulmonary Damage

Stopped: Acute COVID-19 treatments have improved significantly leading to decreased use of ventilatory support. This, coupled with approval of a vaccine, has changed the profile/prognosis of patients and led to a lack of patients with long-term hypoxia.

United States0Started 2020-10-05

Plain-language summary

This clinical trial will explore the safety and potential efficacy of CLBS119 for the repair of COVID-19 induced pulmonary damage in adults.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Initial diagnosis with COVID-19 based on nasopharyngeal, oropharyngeal, or tracheobronchial aspirate SARS CoV-2 RT-PCR test * Receiving or received ventilatory support for COVID-19 pneumonia/ARDS * Evidence for ongoing pulmonary involvement based on P/F ratio \<300 * Able to provide informed consent Exclusion Criteria: * Immunocompromised or current use of immunosuppressive agents other than corticosteroids * History of autoimmune disease * Evidence of multiorgan failure * Subject is pregnant or lactating at the time of signing the consent * Participation in any other clinical trial of an experimental treatment for COVID-19 * History of sickle cell disease

What they're measuring

Adverse events

Timeframe: Through end of study (6 months)

Trial details

NCT IDNCT04522817

SponsorLisata Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-05

View on ClinicalTrials.gov More Covid-19 trials